Combined targeting of CDK4/6 and AKT efficiently inhibits cyclin D/CDK4-6/Rb and PI3K/AKT-mTOR pathways in ER+ breast cancer cell lines. The gene discussed is PIK3CA; the disease is breast carcinoma.